Review Series 10.1172/JCI124607
1Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
2Christine Kühne – Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
Address correspondence to: Mübeccel Akdis, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Oberestrasse 22, CH-7270 Davos Platz, Switzerland. Phone: 41.0.814100848; Email: akdism@siaf.uzh.ch.
Find articles by van de Veen, W. in: JCI | PubMed | Google Scholar
1Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
2Christine Kühne – Center for Allergy Research and Education (CK-CARE), Davos, Switzerland.
Address correspondence to: Mübeccel Akdis, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Oberestrasse 22, CH-7270 Davos Platz, Switzerland. Phone: 41.0.814100848; Email: akdism@siaf.uzh.ch.
Find articles by
Akdis, M.
in:
JCI
|
PubMed
|
Google Scholar
|
First published March 18, 2019 - More info
The rising prevalence of allergies represents an increasing socioeconomic burden. A detailed understanding of the immunological mechanisms that underlie the development of allergic disease, as well as the processes that drive immune tolerance to allergens, will be instrumental in designing therapeutic strategies to treat and prevent allergic disease. Improved characterization of individual patients through the use of specific biomarkers and improved definitions of disease endotypes are paving the way for the use of targeted therapeutic approaches for personalized treatment. Allergen-specific immunotherapy and biologic therapies that target key molecules driving the Th2 response are already used in the clinic, and a wave of novel drug candidates are under development. In-depth analysis of the cells and tissues of patients treated with such targeted interventions provides a wealth of information on the mechanisms that drive allergies and tolerance to allergens. Here, we aim to deliver an overview of the current state of specific inhibitors used in the treatment of allergy, with a particular focus on asthma and atopic dermatitis, and provide insights into the roles of these molecules in immunological mechanisms of allergic disease.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.